IMRX News and Press, Immuneering Corporation From 03/06/23

2023-03-06 22:50:05 ET Immuneering Corporation (IMRX) Q4 2022 Earnings Conference Call March 6, 2023 4:30 PM ET Company Participants Laurence Watts - Investor Relations, Gilmartin Group Benjamin Zeskind - President and Chief Executive Officer Brett Hall - Chief S...

2023-03-06 17:19:53 ET Immuneering press release ( NASDAQ: IMRX ): Q4 GAAP EPS of -$0.50 beats by $0.08 . Cash, cash equivalents and marketable securities as of December 31, 2022 were $105.5 million, compared with $150.2 million as of December 31, 2021. Based ...

First patient dosed in Phase 1/2a clinical trial of IMM-1-104 in advanced solid tumors with any RAS mutation Provides debut guidance for IMM-1-104 program: initial Phase 1 PK and safety data expected in mid-2023, initial Phase 1 PD modeling and additional PK and safety data expected...

Broad response demonstrated through deep cyclic inhibition of MAPK pathway, independent of specific RAS mutation Phase 1/2a clinical trial with IMM-1-104 underway in patients with advanced solid tumors harboring RAS mutations CAMBRIDGE, Mass., March 05, 2023 (GLOBE NEWSWIRE) -- Im...

CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that it plans to release financial re...

Immuneering Corporation ( NASDAQ: IMRX ) traded lower Friday after Morgan Stanley downgraded the clinical-stage biotech to Underweight from Equal Weight, noting that the company lacks clear clinical catalysts this year. Despite the bearish rating, analyst Jeffrey Hung doesn't project ...

CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical stage biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activating events, today announced that management...

IMM-1-104 being tested in first all-comers RAS clinical trial believed to be conducted to date First patient dosed follows swiftly from IND clearance at the end of September CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clini...

Immuneering press release ( NASDAQ: IMRX ): Q3 GAAP EPS of -$0.49 in-line. Revenue of $38.38M (-92.0% Y/Y). Cash and cash equivalents and marketable securities as of September 30, 2022, were $117.2 million, compared with $150.2 million as of December 31, 2021. Fo...

Recruiting has Commenced for Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations (NCT05585320), with the First Patient Expected to be Dosed this Quarter Shares Promising Preclinical Data on Second Program IMM-6-415 at the 37 th Annual M...